Primary navigation

    Brilinta

    Drugs - Brilinta (ticagrelor) [AstraZeneca]

    November 2011

    Therapeutic area - Anticoagulants

    Approval criteria

    • Patient has diagnosis of either; unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction AND
    • Patient is taking ≤ 100 mg of aspirin daily

    Supply limit

    • Quantity limit = 68 tablets

    Background information

    BRILINTA is a P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) (unstable angina, non-ST elevation myocardial infarction, or ST elevation myocardial infarction). BRILINTA has been shown to reduce the rate of a combined endpoint of cardiovascular death, myocardial infarction, or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with PCI, it also reduces the rate of stent thrombosis.

    BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily.

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top